About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Advances in medicine have resulted in some unintended consequences that will require vim and vigor to address.
Thomas Marzili, MD
The author reviews the need to protect health care workers and first responders against potential smallpox outbreaks in the community
Timothy J. Babinchak, MD
Dr. Vogenberg discusses trends in pharmaceutical costs and the challenges involved in making medications accessible.
F. Randy Vogenberg, RPh, PhD
A Cohort Study of NSAID Use and the Management of Related Gastrointestinal Symptoms by Primary Care Patients
Many patients continue taking nonsteroidal anti-inflammatory drugs despite GI side effects and tend not to consult their physicians.
Christopher V. Chambers, MD, Walter L. Straus, MD, MPH, James J. Diamond, PhD, Lori A. Trapani, BS, BSN, RN, Mary Weeks, MS, and Nicole Somvanshi, MD
Principles of Antibiotic Formulary Selection for P&T Committees, Part 2: Pharmacokinetics and Pharmacodynamics
Burke A. Cunha, MD
Testing the Mettle of Iron Prescribing: Optimizing Oral Iron Therapy
Pressure Ulcers: What to Think When Giving Zinc
Emerging Palliative Treatment Options
Anne Mahoney, BA, and Ronald E. Polk, PharmD
Editor-in-Chief David Nash, MD, MBA, discusses the paradox of low-molecular-weight heparins in hospitalized patients with deep vein thrombosis.
David B. Nash, MD, MBA
Matthew Grissinger discusses the confusion that sometimes occurs with supplements that contain
Matthew Grissinger, RPh
Stephen Barlas describes the proposed Medicare drug benefit bill and the convolutions involved in its passage.
P&T presents the latest information about approvals, indication changes, industry updates, and news from the FDA.
The authors review atomoxetine (Strattera®) for the treatment of ADHD.
Robert Carter, PharmD, Marlon Honeywell, PharmD, Tawana Carter, PharmD, Evans Branch III, PharmD, Bishop Hollifield, PharmD, and Michael Thompson, BCNSP, PharmD